FeesSafety
Pluang+

Privosegtor shows neuroprotective effects in Phase 2 trial for optic neuritis, reducing nerve damage markers.

Company Fundamentals
22 Oct 2026
Na
View Source
Bullish
Privosegtor shows neuroprotective effects in Phase 2 trial for optic neuritis, reducing nerve damage markers.

Oculis Holding AG announced that Privosegtor, in a Phase 2 ACUITY trial, reduced increases in blood biomarkers linked to nerve damage (NfL and GFAP) in patients with optic neuritis compared to placebo. These biomarker improvements support earlier findings of better visual function and retinal preservation, indicating Privosegtor's potential as a neuroprotective therapy. The drug, which crosses the blood-brain barrier, is also being explored for acute multiple sclerosis relapses. Oculis plans further clinical development under its PIONEER program, aiming to address significant unmet needs in neuro-ophthalmology and neuro-axonal diseases.

Oculis Holding AG's recent clinical data on Privosegtor comes as 70 of 150 priced Health-sector US stocks on Pluang rose while 79 fell. Notable movers include Illumina, Inc. (ILMN) with a price of USD 281.50 and a 1-day change of +5.06%, Avantor Inc. (AVTR) at USD 17.40 with +4.69%, and Novavax Inc. (NVAX) at USD 10.90 with -4.64%. Pluang order activity shows ILMN favored by buyers at 68%, while NVAX sees heavy selling at 99%. Typical hold times range from 9 days for AVTR to 83 days for ILMN, as of Oct 22, 2026 12:11 WIB.

More News

Ipsen raises 2026 sales growth forecast to 23% after strong Q3 performance

Ipsen raises 2026 sales growth forecast to 23% after strong Q3 performance

Ipsen reported a 24.6% sales growth at constant exchange rates for the first nine months of 2026, driven by strong performance in Oncology, Rare Disease, and Neuroscience segments. The company upgraded its full-year sales growth guidance to around 23...

Company Fundamentals
Bullish
1 hour ago
Nexans chosen as preferred supplier for Mallorca-Menorca power cable project to boost Balearic Islands' grid resilience.

Nexans chosen as preferred supplier for Mallorca-Menorca power cable project to boost Balearic Islands' grid resilience.

Nexans has been selected by Red Eléctrica as the preferred supplier for the Mallorca-Menorca 3 interconnection project, a key infrastructure initiative aimed at strengthening the electricity network's security and resilience in the Balearic Islands. ...

Market News
Bullish
1 hour ago
Roche posts 7% sales growth in Q3 2026, driven by strong demand for innovative medicines and diagnostics.

Roche posts 7% sales growth in Q3 2026, driven by strong demand for innovative medicines and diagnostics.

Roche reported a 7% sales increase at constant exchange rates in Q3 2026, with a 6% rise for the first nine months, fueled by high demand for key medicines like Xolair, Hemlibra, and Ocrevus. The Pharmaceuticals Division led growth, while Diagnostics...

Company Fundamentals
Bullish
1 hour ago
Nexans chosen as preferred supplier for Mallorca-Menorca power interconnection project with Red Eléctrica.

Nexans chosen as preferred supplier for Mallorca-Menorca power interconnection project with Red Eléctrica.

Nexans has been selected by Red Eléctrica as the preferred supplier for the Mallorca-Menorca 3 interconnection project, aimed at enhancing the electricity network's security and resilience in the Balearic Islands. The project includes a six-month eng...

Market News
Bullish
1 hour ago
Nexans reports 10.1% revenue growth in 9M 2026, confirms 2026 outlook with strong performance in electrification segments.

Nexans reports 10.1% revenue growth in 9M 2026, confirms 2026 outlook with strong performance in electrification segments.

Nexans posted a 10.1% increase in revenue to €4.95 billion for the first nine months of 2026, driven by strong organic growth in its electrification segments PWR-Grid and PWR-Connect. The company successfully integrated Republic Wire in the US and co...

Company Fundamentals
Bullish
1 hour ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App